This inventor holds 1 USPTO granted patent. Top assignee: Large Scale Biology Corporation. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: The Innovative Contributions of Daniel Tusé
Introduction
Daniel Tusé is a notable inventor based in Menlo Park, California. He has made significant strides in the field of cancer treatment through his innovative work on self-antigen vaccines. His research focuses on developing effective therapies for B cell lymphomas and other cancers.
Latest Patents
Daniel Tusé holds a patent for "Self antigen vaccines for treating B cell lymphomas and other cancers." This patent describes a polypeptide self-antigen that is useful in a tumor-specific vaccine. The polypeptide mimics one or more epitopes of an antigen uniquely expressed by tumor cells. It is produced in a plant that has been transformed with nucleic acid encoding the polypeptide, allowing it to be obtained in a correctly folded, soluble form without the need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without requiring exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma. He has been granted 1 patent for this groundbreaking work.
Career Highlights
Daniel Tusé is associated with Large Scale Biology Corporation, where he continues to contribute to advancements in biotechnology and cancer treatment. His work has the potential to revolutionize how certain cancers are treated, providing new hope for patients.
Collaborations
Some of his notable coworkers include Alison A McCormick and Stephen J Reinl, who collaborate with him in his research endeavors.
Conclusion
Daniel Tusé's innovative work in developing self-antigen vaccines represents a significant advancement in cancer treatment. His contributions are paving the way for new therapeutic options for patients suffering from B cell lymphomas and other cancers.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile